STOCK TITAN

Quantum BioPharma Provides Corporate Update

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Quantum BioPharma (NASDAQ: QNTM) has announced the renewal of two service contracts. The company has extended its agreement with King Tide Media for a one-month term starting April 1, 2025, at a cost of US$15,000. Additionally, they have renewed services with IR Agency for a 60-day period beginning April 1, 2025, for US$50,000.

Quantum BioPharma (NASDAQ: QNTM) ha annunciato il rinnovo di due contratti di servizio. L'azienda ha esteso il suo accordo con King Tide Media per un periodo di un mese a partire dal 1 aprile 2025, al costo di 15.000 dollari. Inoltre, hanno rinnovato i servizi con IR Agency per un periodo di 60 giorni a partire dal 1 aprile 2025, per 50.000 dollari.

Quantum BioPharma (NASDAQ: QNTM) ha anunciado la renovación de dos contratos de servicio. La compañía ha extendido su acuerdo con King Tide Media por un periodo de un mes a partir del 1 de abril de 2025, a un costo de 15,000 dólares. Además, han renovado los servicios con IR Agency por un periodo de 60 días a partir del 1 de abril de 2025, por 50,000 dólares.

Quantum BioPharma (NASDAQ: QNTM)은 두 개의 서비스 계약 갱신을 발표했습니다. 이 회사는 King Tide Media와의 계약을 2025년 4월 1일부터 시작하는 한 달 동안 연장했으며, 비용은 15,000달러입니다. 또한, IR Agency와의 서비스도 2025년 4월 1일부터 시작되는 60일 동안 갱신했으며, 비용은 50,000달러입니다.

Quantum BioPharma (NASDAQ: QNTM) a annoncé le renouvellement de deux contrats de service. L'entreprise a prolongé son accord avec King Tide Media pour une durée d'un mois à compter du 1er avril 2025, pour un coût de 15 000 dollars. De plus, ils ont renouvelé les services avec IR Agency pour une période de 60 jours commençant le 1er avril 2025, pour 50 000 dollars.

Quantum BioPharma (NASDAQ: QNTM) hat die Verlängerung von zwei Dienstleistungsverträgen angekündigt. Das Unternehmen hat seine Vereinbarung mit King Tide Media um einen Monat ab dem 1. April 2025 verlängert, zu einem Preis von 15.000 US-Dollar. Darüber hinaus haben sie die Dienstleistungen mit IR Agency für einen Zeitraum von 60 Tagen ab dem 1. April 2025 für 50.000 US-Dollar erneuert.

Positive
  • None.
Negative
  • Increased operational expenses of US$65,000 for service contracts

Toronto, Ontario--(Newsfile Corp. - March 30, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has renewed the services of King Tide Media LLC based at 806E Windward Way, Suite 816, Lake Worth, Florida for a 1-month term commencing April 1, 2025 for US$15,000 and IR Agency LLC based at 23 Downing Street, Newark NJ 07105, commencing April 1, 2025 for 60 days for US$50,000.

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit www.quantumbiopharma.com.

For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.

Forward-Looking Information

This press release contains certain "forward-looking statements" within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "anticipates", "expects", "is expected", "scheduled", "estimates", "pending", "intends", "plans", "forecasts", "targets", or "hopes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "will", "should" "might", "will be taken", or "occur" and similar expressions) are not statements of historical fact and may be forward-looking statements.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's assessment of market conditions, its ability to gain market share, and its potential competitive edge are accurate; the Company will have the ability to carry out its plans with respect to its new innovation and offerings.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to the risks discussed in the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024, under the heading "Risk Factors". These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Readers are cautioned that the foregoing list is not exhaustive. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events, or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts:

Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246657

FAQ

How much is Quantum BioPharma (QNTM) spending on service contracts in April 2025?

QNTM is spending a total of US$65,000 on service contracts with King Tide Media ($15,000) and IR Agency ($50,000).

What is the duration of QNTM's contract with IR Agency ?

QNTM's contract with IR Agency is for 60 days, starting April 1, 2025.

When do the new service contracts for Quantum BioPharma (QNTM) begin?

Both service contracts begin on April 1, 2025.

Which service providers has Quantum BioPharma (QNTM) renewed contracts with?

QNTM has renewed contracts with King Tide Media and IR Agency
Quantum BioPharma Ltd

NASDAQ:QNTM

QNTM Rankings

QNTM Latest News

QNTM Stock Data

14.72M
1.66M
11.46%
14.84%
2.56%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Toronto